5-[[4-(4-Fluorophenoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[[4-(4-Fluorophenoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione
• 化学式: C₁₆H₁₂FNO₃S
• 分子量: 317.3
• InChiKey: CTHLPRKJKDPGKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] NOVEL HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2015097713A1

  公开（公告）日：2015-07-02

  The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一种新颖的一般式（I）的GPR 40激动剂，其互变异构体、立体异构体、药用盐、含有它们的药物组合物、它们的制备方法、这些化合物在医学中的应用以及它们制备中涉及的中间体。
• Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
  申请人：Ayer B. Michelle

  公开号：US20050165072A1

  公开（公告）日：2005-07-28

  Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.

  Aryl-link-aryl噻唑烷二酮和aryl-link-aryl噁唑烷二酮化合物是钠通道阻滞剂；其中包括有效量的aryl-link-aryl噻唑烷二酮和aryl-link-aryl噁唑烷二酮化合物以及药学上可接受的载体的制药组合物，以及通过给予有效量的aryl-link-aryl噻唑烷二酮和aryl-link-aryl噁唑烷二酮化合物的方法治疗急性疼痛、慢性疼痛、内脏疼痛、炎症性疼痛或神经病性疼痛，以及易激性肠综合症、克罗恩病、癫痫、部分和全身强直性发作、多发性硬化、双相抑郁症和快速心律失常。
• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20160257701A1

  公开（公告）日：2016-09-08

  The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及一种新的GPR 40激动剂，其通式为（I），它们的互变异构体，立体异构体，药学上可接受的盐，包含它们的制药组合物，制备它们的方法，这些化合物在医学上的使用以及其制备中涉及的中间体。
• Heterocyclic compounds
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US10011609B2

  公开（公告）日：2018-07-03

  The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及通式（I）的新型 GPR 40 激动剂、它们的同分异构体、它们的立体异构体、它们的药学上可接受的盐、含有它们的药物组合物、它们的制备方法、这些化合物在医学中的用途以及制备它们所涉及的中间体。
• EP1501509A4
  申请人：——

  公开号：EP1501509A4

  公开（公告）日：2009-07-15